FERROUS SULFATE 300 mg
Natural health product licensed in Canada
- Other names
- APO-FERROUS SULFATE
- Licence holder
- Apotex Inc.
- NPN or DIN-HM
- 01912518
- Status
- Active licence
- Licence date
- 13 August 2008
- Revision date
- 17 December 2009
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- DIN de transition
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
FD & C Jaune no. 6, Eau purifiée, Stéarate de magnésium, Microcrystalline cellulose, D & C Red #7 Lake, Poly(éthylène glycol), Croscarmellose de sodium, Hydroxypropylcellulose, Hydroxypropylméthylcellulose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Comprimé | minimum: 1 Tous les jours ; maximum: 3 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Source of iron. Helps with fatigue, weakness, shortness of breath associated with iron deficiency.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Prolonged administration of iron should be avoided except in patients with continued bleeding, malabsorption syndromes that benefit from additional iron that benefit from addition iron therapy or repeated pregnancies. Orally administered iron salts may not be well absorbed in patients with steatorrhea and those who have had a partial gastrectomy.
- Contre-indications
Hemosiderosis, hemochromatosis. Iron compounds are also contraindicated in the treatment of anemia other than iron deficiency. Administration of iron to premature infants with Vitamin E deficiency may precipitate red cell hemolysis. Therefore vitamin E deficiency should also be corrected if possible. Do not administer oral preparations concomitantly with parenteral iron.
- Effets indésirables connus
Oral ingestion of iron preparations may be associated with gastrointestinal discomfort (such as nausea) or epigastric pain, dose related bowel effects (such as constipation or diarrhea) and dark stools. Untoward effects usually subside with continuation of therapy or by iron ingestion with or after meals or by initiating therapy at lower doses and gradually increasing to the therapeutic dose.
Source
Official Health Canada record, licence 01912518
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2009. Photograph the packaging to check whether it has changed. Photograph the packaging